AIR001: Ph I/II started

Mast Therapeutics said the University of Pittsburgh, (Pittsburgh, Pa.) began an open-label, dose-escalation, U.S. Phase I/II trial to evaluate AIR001. Mast will provide the compound and nebulizers for...